The bioelectronic medicine developer has been snapped up by Astellas, two years after the latter took part in its series A round.
Q&A with Rob Coppedge, chief executive, EHV
The short bowel syndrome therapy developer has added $110m to the $35m with which it emerged from stealth in January.
Taiho Ventures and SR One co-led a series A round that will fund the early clinical progress of Dren's cancer and protein-depletion drug candidates.
Evotec and Boehringer Ingelheim Venture Fund returned in a $25.9m round for the autoimmune disease drug developer having first invested three years ago.
The round was led by $8m from Leaps by Bayer and increased the microbiome skin treatment developer's total funding to $34m.
Roche and Novo-backed small molecule therapy developer Aligos Therapeutics has floated in an initial public offering priced in the middle of its range.
Nan Fung-backed hearing aid producer Eargo's shares opened at double its IPO price after it floated above its range.
Eli Lilly will acquire the AbbVie-backed neurological disease therapy developer in a $135m transaction that could top $1.2bn with milestone payments.
Instylla, developer of a blood-flow control system, has completed a $25.4m series B round featuring returning investor Ascension Ventures.
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
